PremiumCompany AnnouncementsBionomics Strategic Shift with Neuphoria Redomiciliation Bionomics announces Australia Supreme Court approves re-domiciliation Bionomics publishes resuls from Phase 2 ATTUNE study of BNC210 PremiumThe FlyBionomics intends to re-domicile to the U.S. Bionomics reports ‘positive’ end-of-Phase 2 meeting with FDA on BNC210 Bionomics initiates patient screening for the Phase 3 AFFIRM-1 trial PremiumThe FlyBionomics presents detailed data on validity, reliability of SUDS Bionomics announces end-of-Phase 2 meeting with FDA, solidifies plan for BNC210 Bionomics price target raised to $10 from $7 at Maxim 
